Project Grant R01AI186371
Award Date
9/10/24
Completion Date
7/31/29
Dollars Obligated
$1.2M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,170,041 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Hawaii (UH) to study the long-term safety and effectiveness of the Dengvaxia dengue vaccine in the Philippines. The key objectives are to determine the baseline dengue virus serostatus of Dengvaxia recipients, assess the long-term safety and effectiveness of the vaccine, and characterize the antibody and...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $294,583 Fast-Track Small Business Innovation Research (SBIR) grant to Mapp Biopharmaceutical, Inc. to develop a novel cost-effective multi-specific therapeutic for dengue. The project aims to identify, manufacture, and characterize anti-dengue therapeutics with a synergistic mode of action, and to evaluate the most promising candidates in...
This federal Project Grant award of $192,888 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate the generation, differentiation, breadth, and persistence of SARS-CoV-2-specific CD4+ and CD8+ T cell responses in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) patients after vaccination and infection. The goal is to provide in-depth knowledge of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $699,339 to the Regents of the University of Michigan to study the transmission dynamics of dengue and Zika viruses across diverse environments in coastal Ecuador. The research aims to characterize the force of dengue infection, assess the impact of environmental and societal factors on virus introduction, and...
This federal Project Grant award, valued at $7,105,240.00 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of an HIV vaccine regimen that elicits both broadly neutralizing antibodies and high-quality T-cell responses. The research program will examine cooperative antibody and T-cell responses in humans, leverage IL-10 inhibitors to safely elicit high-quality CD8+...
This $800,389 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective of this 5-year grant is to evaluate the safety and therapeutic potential of a novel treatment strategy for achieving sustained HIV remission. The proposed approach combines soluble IL-15/IL-15RA-FC with TGF-beta pathway blockade and therapeutic vaccination, to enhance anti-viral immunity and...
This federal Project Grant award, with a total funding amount of $778,829, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award's objective is to characterize early-life B-cell and antibody-secreting cell (ASC) development and function in the human spleen, in order to uncover the mechanisms of adaptive immunity operating at birth. The research will test the hypothesis that the human...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel T cell-based vaccine to prevent infection from dengue virus (DENV) and Zika virus (ZIKV). The $781,718 award to Loyola University of Chicago's Health Sciences Campus aims to create a vaccine targeting the non-structural protein 3 (NS3) of ZIKV and DENV1-4, using ubiquitination and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $924,000.00 in funding to Tufts University School of Medicine to support research aimed at mitigating the adhesion of Plasmodium falciparum-infected red blood cells to the vascular endothelium, which is a key contributor to the severe complications of cerebral malaria. The research project, running from July...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $705,557.00 to Emory University to conduct research on the coordination of innate and cellular mucosal immunity in SARS-CoV-2 clearance. The research aims to determine the contribution of monocytes in promoting T cell responses and viral control within the respiratory tract, as well as define the effector mechanisms of...